Resistance in Candida albicans: Exploring the Cell Wall Barrier by Proteomics

The incidence of candidiasis has dramatically increased and bloodstream infections due to different species of\udCandida are becoming a prime cause of morbidity and mortality in different types of immunocompromised patients.\udAzole and echinocandin drug resistance accounts for the dramatic increase in incidence of nosocomial bloodstream\udcandidiasis found in recent years. Cell wall constitutes the barrier between the yeast and the host and resistant\udstrains change the proteome of this compartment. In the last decade different proteomic platforms have been\udapplied to study cell wall and markers of resistance to drugs have been pointed out. Modulation of these proteins\udseem to suggest that although resistance is based on a specific mutation able to counteract the toxicity of the\udantifungal drug, a set of other molecular modifications takes place contemporary or subsequently the establishment\udof the resistance and seems to support the viability of the resistant yeast. Profiled proteins by proteomics may be\udvaluable in design therapy using classical antifungal along with complementary drugs able to abolish pathways that\udstrengthen the resistance and attenuate virulence of the mutated cell